My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 342

    1.

    Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

    Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

    Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708. PMID: 12832314 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

    Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

    Diabetes Care. 2004 Jun;27(6):1265-70.PMID: 15161773 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

    Plosker GL, Figgitt DP.

    Pharmacoeconomics. 2004;22(6):389-411. Review.PMID: 15099124 [PubMed - indexed for MEDLINE]Related articles

    4.

    Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

    Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

    J Clin Pharm Ther. 2009 Feb;34(1):13-23.PMID: 19125899 [PubMed - indexed for MEDLINE]Related articles

    5.

    Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

    Horton ES, Foley JE, Shen SG, Baron MA.

    Curr Med Res Opin. 2004 Jun;20(6):883-9.PMID: 15200747 [PubMed - indexed for MEDLINE]Related articles

    6.

    Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

    Raskin P, McGill J, Saad MF, Cappleman JM, Kaye W, Khutoryansky N, Hale PM; Repaglinide/Rosiglitazone Study Group.

    Diabet Med. 2004 Apr;21(4):329-35.PMID: 15049934 [PubMed - indexed for MEDLINE]Related articles

    7.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    8.

    PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.

    Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA.

    Diabetes Care. 2005 Sep;28(9):2093-9.PMID: 16123472 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.

    Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, Ni Z, Yu H, Liang J, Luo R, Li Y, Huang L.

    Diabetes Obes Metab. 2007 Jul;9(4):558-65.PMID: 17587398 [PubMed - indexed for MEDLINE]Related articles

    10.

    Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

    Diabetes Care. 2000 Nov;23(11):1660-5.PMID: 11092289 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.

    Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA.

    Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51.PMID: 15324515 [PubMed - indexed for MEDLINE]Related articles

    12.

    Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.

    Gerstein HC, Garon J, Joyce C, Rolfe A, Walter CM.

    Diabet Med. 2004 Nov;21(11):1200-3.PMID: 15498086 [PubMed - indexed for MEDLINE]Related articles

    13.

    The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients.

    Soegondo S, Subekti I, Luthariana L.

    Acta Med Indones. 2004 Jul-Sep;36(3):142-7.PMID: 15557683 [PubMed - indexed for MEDLINE]Related articles

    14.

    Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.

    Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM.

    Diabetes Res Clin Pract. 2004 Feb;63(2):127-34.PMID: 14739053 [PubMed - indexed for MEDLINE]Related articles

    15.

    Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.

    Ristic S, Collober-Maugeais C, Pecher E, Cressier F.

    Diabet Med. 2006 Jul;23(7):757-62.PMID: 16842480 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

    Clin Ther. 2007 Nov;29(11):2374-84.PMID: 18158078 [PubMed - indexed for MEDLINE]Related articles

    17.

    Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

    Hirschberg Y, Karara AH, Pietri AO, McLeod JF.

    Diabetes Care. 2000 Mar;23(3):349-53.PMID: 10868864 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

    Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group.

    Clin Ther. 2004 Dec;26(12):2034-44. Erratum in: Clin Ther. 2005 Jul;27(7):1112. PMID: 15823767 [PubMed - indexed for MEDLINE]Related articles

    19.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.

    Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E.

    Diabetes Obes Metab. 2007 Jul;9(4):506-11.PMID: 17587393 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity